

NOVEL EFFECT BIOMARKERS FOR METABOLIC DISRUPTORS: EVIDENCE ON HEALTH IMPACTS TO SCIENCE AND POLICY NEEDS

WHAT WE STUDY

How exposure to metabolism disrupting chemicals (MDCs) present in the environment, food, and consumer products alter our body's normal metabolism processes and cause diseases, such as fatty liver and type 2 diabetes.

OBJECTIVE 1
Generate a unified approach to identify MDCs.

OBJECTIVE 2
Study the adverse effects of MDCs in target organs.

OBJECTIVE 3
Study human exposure to MDCs and identify novel biomarkers of exposure.

OBJECTIVE 4
Improve the risk assessment of MDCs.

OBJECTIVE 5
Increase awareness of MDCs and promote positive health behaviors.

HOW TO TACKLE THE NEMESIS

- Identify relevant MDC-mixtures from human biomonitoring data across Europe
- Use state-of-the-art *in vitro* and *in vivo* methods to study the mechanisms of disruption and identify novel biomarkers of exposure
- Improve risk assessment of MDCs
- Engage citizens in the development of chemical policies

PROJECT DETAILS

NEMESIS project is funded by the European Union, Horizon Europe program.

Grant Agreement no.: 101137405
Duration: 1.1.2024 - 31.12.2028
Grant amount: 7 881 685.25 €

Project coordination:
Professor Jaana Rysä
University of Eastern Finland,
School of Pharmacy
jaana.rysa@uef.fi

NEMESIS

Project partners

University of Eastern Finland
IKP Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie
Karolinska Institutet
Charité Universitätsmedizin Berlin
Tampere University
UHASSELT Knowledge in Action
ISPA Instituto de Investigación Sanitaria del Principado de Asturias
FINBA Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturias
NovaMechanics Cheminformatics & Nanoinformatics Excellence
Aristotle University of Thessaloniki
Umeå University
University of Oulu
ULB Université Libre de Bruxelles
CSIC Consejo Superior de Investigaciones Científicas
NOVA National School of Public Health